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Objectives
• Describe the rationale behind the use of ATG in alloHCT
• Explain the impact of ATG on infectious complications of alloHCT 
Results -Study Participants

Results -Infection Rates
• Factors other than ATG use with significant impact on infection incidence in multivariate analysis: 
Mean Infection Count per Subject by ATG Group and Conditioning Regimen
Results -Infection Rates
Infection Type and Frequency by ATG Group in RIC Patients
RIC nonATG
RIC ATG
Results -Graft versus Host Disease
Limitations
• Data collection limited to day +180
• Difficult to detect true differences in GVHD rates as per protocol at UNCH most higher risk patients (MUD, MMRD) receive ATG
• Infection data limited to culture-documented infections
Conclusions and Future Directions
• ATG use is associated with increased infection rates in alloHCT patients, with greater impact in the RIC setting  Greatest increase is seen in rate of viral infections (CMV, HSV, HHV-6)
• ATG use does not appear to be associated with an increase in mortality in the first 180 days post-HCT
• In the future, we plan to further examine outcomes related to increased infection rates and assessing all outcomes beyond day +180
